<h3>Background</h3> Biological therapy is a major therapeutic tool to prevent clinical and radiological progression of rheumatoid arthritis (RA). On the other hand, adverse effects of these medications are a problem in clinical practice. <h3>Objectives</h3> The aim of this study was to describe and compare the most frequent adverse events with the use of biologic therapy in patients with RA in a real-life ambulatory setting. <h3>Methods</h3> A descriptive study was done by nursing service. A review of adverse event reports presented in pharmacovigilance committee was completed monthly during last 36 months in a specialized in RA center in Colombia. Descriptive epidemiology was used, percentages and averages were calculated. <h3>Results</h3> 570 patients were using biological therapy in a cohort of 2214 RA patients last 36 months. Were 490 women (85.9%) and 80 (14.0%) men. Mean age 60.7 years old. In 163 (28.5% of all) patients were reported adverse events (AE); AE were categorized according WHO classification in mild, moderate and severe; between them 59 (36.2%) were mild, 97 (59.5%) were moderate and 7 (4.2%) were severe. From 163 AE reported, 86 (52.7%) were systemic and 77 (47.2%) dermatologic reactions. Regarding therapeutic approach in 63 patients (38.6%) biologic was temporarily suspended, in 57 (34.9%) was permanently withdrawn and patients switched to another biological, and 43 (26.3%) patients were followed for drug and reactions surveillance. Concerning to type of biologic in 120 patients (73.6%) AE were with anti-TNF therapies. <h3>Conclusions</h3> AE using biologics documented in patients of a specialized RA center are similar to those reported in literature; Biological therapy is considered a safe and recommended treatment for management of RA. AE were more common with anti-TNFs therapies. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5438